Drug Trial Radar · NCT07623798
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
May 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
Pomalidomide CapsulesDrug
1. The DPd treatment regimen, one cycle every 28 days: Pomalidomide 4mg/d orally, on days 1-21; 2. The PVd treatment regimen, one cycle every 21 days: Pomalidomide 4 mg/d orally, on days 1-14 of each treatment cycle;
Bortezomib for InjectionDrug
The PVd treatment regimen, with one cycle every 21 days: Bortezomib on days 1, 4, 8, and 11 of cycles 1-8, and on days 1 and 8 from cycle 9 onwards.
Daratumumab Injection (Subcutaneous Injection)Drug
The DPd treatment regimen, one cycle every 28 days: on days 1, 8, 15, and 22 of cycles 1 and 2; on days 1 and 15 from cycles 3-6; and on day 1 from cycle 7 onwards.
IBI3003Drug
According to body weight
Selinexor TabletsDrug
The SVd treatment regimen, with one cycle every 35 days: Bortezomib on days 1, 8,15,22 and 29 ,100 mg/d orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by independent review committeeTime frame: up to 24 months after the last enrolled participant receives the first dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ZhongShan Hospital FuDan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.